相关实验视频

Updated: Jul 10, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

虹膜糖化物Cornuside通过抑制炎症和调节β细胞功能来缓解妊娠期糖尿病的症状

Xiaorong Cui¹, Yani Yu¹, Jia Yu¹

¹Department of Gynecology, Zibo Central Hospital, Zibo, China.

Gynecologic and obstetric investigation

|November 19, 2023

概括

康努西德 (CNS) 通过促进胰腺β细胞功能和减少炎症来改善妊娠糖尿病 (GDM). 这种天然化合物增强胰岛素分泌,并减轻小鼠的GDM症状.

科学领域:

药理学药理学是指药理学的学科.
内分泌学在内分泌学.
生殖生物学生殖生物学

背景情况:

孕期糖尿病 (GDM) 是一种常见的妊娠并发症,具有重大风险.
胰腺β细胞功能障碍和炎症是GDM发展的关键因素.
角化物 (CNS),一种虹膜糖化物,具有已知的抗炎性质.

研究的目的:

研究Cornuside (CNS) 对胰腺β细胞和GDM的治疗作用.
为了阐明中枢神经系统在GDM病变发生过程中的作用的基本机制.

主要方法:

用不同度的中枢神经系统治疗MIN6β细胞系,以评估胰岛素的产生和分泌.
在接受治疗的MIN6细胞中分析关键基因表达 (Pdx1,Rac1,Piezo,NeuroD1) 和细胞增殖.
将中枢神经系统给予GDM小鼠模型,以评估GDM症状的改善,炎症标志物水平 (IL-6,TNF-α) 和NF-κB激活.

主要成果:

中枢神经系统显著促进了MIN6细胞的增殖,增强了胰岛素含量和分泌.
中枢神经系统治疗提高了β细胞中Pdx1,Rac1,Piezo和NeuroD1的表达.
中枢神经系统的使用缓解了小鼠的GDM症状,降低了血清IL-6和TNF-α水平,并抑制了胎盘NF-κB的激活.

结论:

科努西德 (CNS) 通过改善β细胞功能,证明了对GDM的治疗潜力.
中枢神经系统通过减轻炎症和增强胰腺β细胞活性来改善GDM.

关键词:

科尔努斯的一面孕期糖尿病是一种糖尿病.炎症炎症是一种炎症.这是β细胞.

更多相关视频

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...